IL172249A0 - Methods for treating protein aggregation disorders - Google Patents
Methods for treating protein aggregation disordersInfo
- Publication number
- IL172249A0 IL172249A0 IL172249A IL17224905A IL172249A0 IL 172249 A0 IL172249 A0 IL 172249A0 IL 172249 A IL172249 A IL 172249A IL 17224905 A IL17224905 A IL 17224905A IL 172249 A0 IL172249 A0 IL 172249A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- protein aggregation
- treating protein
- aggregation disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48091803P | 2003-06-23 | 2003-06-23 | |
| US51201703P | 2003-10-17 | 2003-10-17 | |
| US87161304A | 2004-06-18 | 2004-06-18 | |
| PCT/IB2004/002405 WO2005000288A2 (en) | 2003-06-23 | 2004-06-21 | Treatment of protein aggregation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL172249A0 true IL172249A0 (en) | 2006-04-10 |
Family
ID=33556419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL172249A IL172249A0 (en) | 2003-06-23 | 2005-11-29 | Methods for treating protein aggregation disorders |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1646375A2 (en) |
| JP (1) | JP2007521255A (en) |
| AU (1) | AU2004251511A1 (en) |
| CA (1) | CA2528627A1 (en) |
| IL (1) | IL172249A0 (en) |
| MX (1) | MXPA05013692A (en) |
| WO (1) | WO2005000288A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1937239A2 (en) * | 2005-09-30 | 2008-07-02 | Neurochem (International) Limited | Pharmaceutical compositions comprising carboxyalkylsulfonic acids |
| SG173405A1 (en) * | 2006-08-04 | 2011-08-29 | Lonza Biologics Plc | Method for predicting protein aggregation and designing aggregation inhibitors |
| EP2285369A2 (en) * | 2008-05-05 | 2011-02-23 | Tiltan Pharma Ltd | Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| US9751834B2 (en) | 2011-05-26 | 2017-09-05 | Gri Bio, Inc. | Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use |
| US9850265B2 (en) | 2011-05-26 | 2017-12-26 | Gri Bio, Inc. | Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use |
| ES2581482T3 (en) | 2011-05-26 | 2016-09-06 | Jado Technologies Gmbh | Hydroxy-substituted amino and ammonium derivatives and their medical use |
| MA47595A (en) | 2017-02-24 | 2020-01-01 | Alzheon Inc | TREATMENT METHODS FOR NEURODEGENERATIVE DISORDERS |
| CN112912732A (en) * | 2018-08-03 | 2021-06-04 | 香港大学 | Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, RNA, and nucleoli |
| WO2021090911A1 (en) * | 2019-11-08 | 2021-05-14 | セントラル硝子株式会社 | Method for selectively killing protein aggregate-containing cells, kit therefor, therapeutic drug for protein misfolding diseases and drug product for removing protein aggregates from blood product |
| CN111500729B (en) * | 2020-05-14 | 2022-02-01 | 中国人民解放军总医院 | Application of plasma lnc-SCA7 in preparation of biomarker for judging whether patient is sensitive to neoadjuvant chemotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| EP0959877A4 (en) * | 1996-04-10 | 2000-08-23 | Univ California | Correction of genetic defects using chemical chaperones |
| US7078191B1 (en) * | 1997-08-01 | 2006-07-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation |
| CA2320556A1 (en) * | 1999-09-29 | 2001-03-29 | Queen's University At Kingston | N,n-dichlorinated omega amino acids and uses thereof |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| US20020155172A1 (en) * | 2000-04-07 | 2002-10-24 | Junying Yuan | Methods and compounds for decreasing cell toxicity or death |
| GB0117326D0 (en) * | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| CA2511599A1 (en) * | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
-
2004
- 2004-06-21 MX MXPA05013692A patent/MXPA05013692A/en not_active Application Discontinuation
- 2004-06-21 JP JP2006516603A patent/JP2007521255A/en not_active Withdrawn
- 2004-06-21 CA CA002528627A patent/CA2528627A1/en not_active Abandoned
- 2004-06-21 AU AU2004251511A patent/AU2004251511A1/en not_active Abandoned
- 2004-06-21 WO PCT/IB2004/002405 patent/WO2005000288A2/en not_active Application Discontinuation
- 2004-06-21 EP EP04744063A patent/EP1646375A2/en not_active Withdrawn
-
2005
- 2005-11-29 IL IL172249A patent/IL172249A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005000288A2 (en) | 2005-01-06 |
| JP2007521255A (en) | 2007-08-02 |
| EP1646375A2 (en) | 2006-04-19 |
| WO2005000288A3 (en) | 2005-05-06 |
| MXPA05013692A (en) | 2006-03-13 |
| CA2528627A1 (en) | 2005-01-06 |
| AU2004251511A1 (en) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249389A0 (en) | Combination therapy for treating protein deficiency disorders | |
| HK1219678A1 (en) | Methods for treating interleukin-6 related diseases -6 | |
| IL172249A0 (en) | Methods for treating protein aggregation disorders | |
| IL169633A0 (en) | Combination therapy for treating protein deficiencies | |
| EP1636359A4 (en) | Methods for treating pain | |
| HK1098383A1 (en) | Compositions and methods for treating coagulation related disorders | |
| IL175818A0 (en) | Method for treating adamts-5- associated disease | |
| PL1655036T3 (en) | Method for treating oncological diseases | |
| AU2003286611A8 (en) | Cytomodulating peptides and methods for treating neurological disorders | |
| EP1696877A4 (en) | Methods for treating pain | |
| IL164352A0 (en) | Methods for treating tweak-related conditions | |
| EP1476147A4 (en) | Methods for treating eye disorders | |
| HK1092180A1 (en) | Methods for treating ischemic diseases | |
| EP1695061A4 (en) | Method for treating neurological disorders | |
| EP1755637A4 (en) | Methods for preventing or treating bone disorders | |
| GB0307544D0 (en) | Treatment method | |
| GB0522915D0 (en) | Methods for recombinant immunoglobulin treatment | |
| GB0302691D0 (en) | Treatment method | |
| AU2003300471A8 (en) | Methods for treating ocular diseases | |
| GB0303430D0 (en) | Treatment methods | |
| GB0315322D0 (en) | Treatment methods | |
| GB0314174D0 (en) | Methods and means for treating codon reiteration disorders | |
| ZA200604552B (en) | Method for treating ADAMTS-5-associated disease | |
| GB0324853D0 (en) | Apparatus for treating movement disorders |